GSK chief backs a centralized European approval process

With European countries slamming the brakes on drug spending whenever possible, GSK chief Andrew Witty took the helm of the continent's pharma association calling for a "new dialogue" between the industry and government officials and cautiously backing a radical revamp of the European approval process. Currently, developers have to gain the endorsement of the EMA prior to seeking marketing approval from the 27 countries in the EU, which assess a product's cost effectiveness. Witty, though,...